Drugs / CAR19TIF cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07009002 | Jun 2025 → May 2026 overdue | lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR19TIF cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07009002 ↗ |
| Modality | Cell therapy | “CD19-targeting chimeric antigen receptor (CAR) T-cell therapy” NCT07009002 ↗ |
| Target | CD19 | “CD19-targeting chimeric antigen receptor (CAR) T-cell therapy” NCT07009002 ↗ |